Crossmark

: R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics. He has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer and serves on advisory boards and/or steering committees for Asceneuron, Bristol Myers Squibb and Biogen. G.S. has received speaker fees from Springer and Adium. S.P. has acquired research support (for the institution) from ki elements (ADDF) and Avid. In the past 2 years, he has received consultancy and/or speaker fees from BioArctic, Biogen, Esai, Lilly and Roche. Research programs of W.M.v.d.F. have been funded by ZonMw, the NWO, EU-JPND, EU-IHI, Alzheimer Nederland, the Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, the Stichting Dioraphte, Gieskes-Strijbis Fonds, the Stichting Equilibrio, Edwin Bouw Fonds, the Pasman Stichting, the Stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA, Novartis-NL, Life-MI, Avid, Roche, Fujifilm, Eisai and Combinostics. W.M.v.d.F. holds the Pasman chair. W.M.v.d.F. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMw (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance, LSHM20106). W.M.v.d.F. is a recipient of TAP-dementia (), receiving funding from ZonMw (10510032120003) in the context of the Onderzoeksprogramma Dementie, part of the Dutch National Dementia Strategy. TAP-dementia receives cofinancing from Avid Radiopharmaceuticals and Amprion. Gieskes-Strijbis Fonds also contributes to TAP-dementia. W.M.v.d.F. has been an invited speaker at Biogen MA, Danone, Eisai, WebMD Neurology (Medscape), Novo Nordisk, Springer Healthcare and the European Brain Council. W.M.v.d.F. is a consultant to the Oxford Health Policy Forum CIC, Roche, Biogen MA and Eisai. W.M.v.d.F. participated in advisory boards of Biogen MA, Roche and Eli Lilly. W.M.v.d.F. is member of the steering committee of EVOKE and EVOKE+ (Novo Nordisk). All funding is paid to her institution. W.M.v.d.F. is member of the steering committee of PAVE and Think Brain Health. W.M.v.d.F. was an associate editor of Alzheimer’s Research and Therapy in 2020 and 2021. W.M.v.d.F. is an associate editor at Brain. E.v.d.G. has performed contract research for Heuron and Roche. E.v.d.G. has a consultancy agreement with IXICO and Life Molecular Imaging for reading PET scans. C.E.T. has research contracts with Acumen, ADx Neurosciences, AC Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant NanoBiosensors, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama and Vivoryon. She is the editor in chief of Alzheimer’s Research and Therapy and serves on editorial boards of Medidact Neurologie/Springer and Neurology: Neuroimmunology & Neuroinflammation. She had consultancy and/or speaker contracts for Eli Lilly, Merck, Novo Nordisk, Olink and Roche. S.E.S. has served as a consultant to Eisai and Novo Nordisk and has received speaker fees from Eli Lilly and Medscape. She has analyzed biomarker data provided by C2N Diagnostics. J.T. has served as a consultant for the Neurotorium educational platform and for Alzheon. P.R.-N. has served on scientific advisory boards and/or as a consultant for Roche, Novo Nordisk, Eisai and Cerveau Radiopharmaceuticals. C.R. has received research grants from the National Health and Medical Research Council, Enigma Australia, Biogen, Eisai and AbbVie. He is on the scientific advisory board for Enigma/Meilleur Technologies and has consulted for Prothena, Eisai, Roche and Biogen Australia. R.J.B. has received laboratory research funding from the National Institutes of Health, the Alzheimer’s Association, the BrightFocus Foundation, the Rainwater Foundation, the Association for Frontotemporal Degeneration FTD Biomarkers Initiative, Avid Radiopharmaceuticals, Janssen, the Tau Consortium, Novartis, Centene, the Association for Frontotemporal Degeneration, the Cure Alzheimer’s Fund, Coins for Alzheimer’s Research Trust Fund, the Foundation for Barnes-Jewish Hospital, the Good Ventures Foundation, the DIAN-TU Pharma Consortium, the Tau SILK Consortium (AbbVie, Biogen, Eli Lilly and an anonymous organization), the NfL Consortium (AbbVie, Biogen, Bristol Meyers Squibb, Hoffmann-La Roche) and the Tracy Family SILQ Center; has equity ownership interest in C2N Diagnostics and receives income based on technology licensed by Washington University to C2N Diagnostics; and receives income from C2N Diagnostics for serving on the scientific advisory board. O.H. has acquired research support (for the institution) from Avid Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy and/or speaker fees from AC Immune, ALZpath, BioArctic, Biogen, Bristol Meyers Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. S.C.J. has served in the past 2 years on advisory boards for Enigma Biomedical and ALZpath. The other authors report no competing interests.

Document is current

Any future updates will be listed below